The 14 linked references in paper A. TARASOVА P., A. KHAVANSKY V., A. TIMOKHINA S., A. DOVGAN P., D. KOSTINA A., L. SERNOV N., А. ТАРАСОВА П., А. ХАВАНСКИЙ В., А. ТИМОХИНА С., А. ДОВГАНЬ П., Д. КОСТИНА А., Л. СЕРНОВ Н. (2017) “КАРДИОПРОТЕКТИВНЫЕ ЭФФЕКТЫ ИНКРИТИНОМИМЕТИКОВ ЭКСЕНАТИДАНА И ВИЛДАГЛИПТИНА ПРИ МОДЕЛИРОВАНИИ ДОКСОРУБИЦИНОВОЙ КАРДИОМИОПАТИИ // CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING” / spz:neicon:ksma:y:2017:i:3:p:100-105

  1. Трунина Е.Н., Петунина Н.А., Чорбинская С.А. Ингибиторы дипептидилпептидазы-4 в лечении сахарного диабета 2 типа. Возможности кардиопротекции. Кардиология. Сахарный диабет. 2011; 2: 59–64.
  2. Ban K., Noyan-Ashraf M.H., Hoefer J.et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Int J Cardiol. 2008; 118(4): 2340-50. DOI:10.1161/circulationaha.107.739938.
  3. Liu Q., Anderson C., Broyde A. et al Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular diabetology. 2010; 9:79. DOI:10.1186/1475-2840-
  4. 1016/j.ijcard.2017.02.126. 10. Hull T.D., Boddu R., Guo L. et al. Heme oxygenase-1 regulates mitochondrial quality control in the heart. Cardiology. 2016; 1(2): 378–383. DOI:10.1172/jci.insight.85817.
  5. Lonborg J., Vejlstrup N., Kelbaek H. et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European heart journal. 2012; 33(12): 14911499. DOI:10.1093/eurheartj/ehr309
  6. Ichikawa Y. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014; 124(2): 617–630. DOI:10.1152/ajpheart.00554.2015.
  7. Kuznetsov A.V., Margreiter R., Amberger A., Saks V. et al. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta. 2011; 1813(6):1144–1152. DOI:10.1152/ajpheart.00554
  8. Kesarev O.G, Danilenko L.M., Pokrovskii M.V. et al. Study ofdose-dependent effect of 2-ethyl-6-methyl-3 hydroxypyridine succinate on the contractile function of isolated rat heat. Research result: pharmacology and clinical pharmacology. 2017; 3: 3-9. DOI:10.18413/2500-235X-2017-3-1-3-9.
  9. Fogli S., Nieri S., Breschi M.C The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. Faseb J. 2004; 18 (6): 664-675. DOI:10.1096/ fj.03-0724rev
  10. Скачилова С.Я., Кесарев О.Г., Даниленко Л.М. Фармакологическая защита ишемизированного миокарда производными 3-(2,2,2-триметилгидразиния) пропионата и оценка их антиоксидантной активности. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2015; 1: 25-31.
  11. Skachilova S.Y., Kesarev O.G., Danilenko L.M. et al. Pharmacological correction of L-NAME-induced oxide deficiency with derivatives of 3-(2,2,2-trimethylhydrazinium) propionate. Research result: pharmacology and clinical pharmacology. 2016; 2: 36-41. Doi:10.18413/23/13-8971-2016-2-1-36-41.
  12. Noyan-Ashraf M.H., Momen M.A., Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009; 58(4): 975–983. DOI:10.2337/db08-1193
  13. Read P.A., Khan F.Z., Dutka D.P. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012; 98(5): 408-413.DOI: 10.1136/hrt.2010.219345.
  14. Vives-Bauza C. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A. 2010; 107(1):378–383. DOI:10.1073/pnas.0911187107.